Department of Molecular Immunology

Laboratory of Antibody Engineering

Chikaev Anton
Senior research fellow

Staff: 
thomson_logo.gif scopus_logo.jpg Chikaev Anton senior research fellow PhD (Biology) chikaevatmcb [dot] nsc [dot] ru
thomson_logo.gif scopus_logo.jpg Kulemzin Sergey senior research fellow PhD (Biology) skulemzinatmcb [dot] nsc [dot] ru
thomson_logo.gif scopus_logo.jpg Guselnikov Sergey senior research fellow PhD (Biology) sguselnikovatmcb [dot] nsc [dot] ru
thomson_logo.gif scopus_logo.jpg Belovezhets Tatiana research fellow   belovezhecatmcb [dot] nsc [dot] ru

Recent publications: 

  1. Guselnikov SV, Baranov KO, Kulemzin SV, Belovezhets TN, Chikaev AN, Murasheva SV, Volkova OY, Mechetina LV, Najakshin AM, Chikaev NA, Solodkov PP, Sergeeva MV, Smirnov AV, Serova IA, Serov OL, Markhaev AG, Kononova YV, Alekseev AY, Gulyaeva MA, Danilenko DM, Battulin NR, Shestopalov AM, Taranin AV. A potent, broadly neutralizing human monoclonal antibody that efficiently protects hACE2-transgenic mice from infection with the Wuhan, BA.5, and XBB.1.5 SARS-CoV-2 variants. (doi: 10.3389/fimmu.2024.1442160) Front Immunol 15: 1442160, 2024

  2. Solodkov PP, Najakshin AM, Chikaev NA, Kulemzin SV, Mechetina LV, Baranov KO, Guselnikov SV, Gorchakov AA, Belovezhets TN, Chikaev AN, Volkova OY, Markhaev AG, Kononova YuV, Alekseev AY, Gulyaeva MA, Shestopalov AM, Taranin AV. Serial llama immunization with various SARS-CoV-2 RBD variants induces broad spectrum virus-neutralizing nanobodies. (doi: 10.3390/vaccines12020129) Vaccines 12(2): 129, 2024

  3. Kulemzin SV, Guselnikov SV, Nekrasov BG, Molodykh SV, Kuvshinova IN, Murasheva SV, Belovezhets TN, Gorchakov AA, Chikaev AN, Chikaev NA, Volkova OY, Yurina AA, Najakshin AM, Taranin AV. Hybrid immunity from Gam-COVID-Vac vaccination and natural SARS-CoV-2 infection confers broader neutralizing activity against omicron lineage VOCs than revaccination or reinfection. (doi: 10.3390/vaccines12010055) Vaccines 12(1): 55, 2024

  4. Sukhova M, Byazrova M, Mikhailov A, Yusubalieva G, Maslova I, Belovezhets T, Chikaev N, Vorobiev I, Baklaushev V, Filatov A. Humoral immune responses in patients with severe COVID-19: a comparative pilot study between individuals infected by SARS-CoV-2 during the wild-type and the delta periods. (doi: 10.3390/microorganisms11092347) Microorganisms 11(9): 2347, 2023

  5. Belovezhets T, Kulemzin S, Volkova O, Najakshin A, Taranin A, Gorchakov A. Comparative pre-clinical analysis of CD20-specific CAR T cells encompassing 1F5-, Leu16-, and 2F2-based antigen-recognition moieties. (doi: 10.3390/ijms24043698) Int J Mol Sci 24(4): 3698, 2023

  6. Nushtaeva A, Ermakov M, Abdurakhmanova M, Troitskaya O, Belovezhets T, Varlamov M, Gayner T, Richter V, Koval O. “Pulsed hypoxia” gradually reprograms breast cancer fibroblasts into pro-tumorigenic cells via mesenchymal–epithelial transition. (doi: 10.3390/ijms24032494) Int J Mol Sci 24(3): 2494, 2023

  7. Yusubalieva GM, Dashinimaev EB, Gorchakov AA, Kulemzin SV, Brovkina OA, Kalinkin AA, Vinokurov AG, Shirmanova MV, Taranin AV, Baklaushev VP. Enhanced natural killers with CISH and B2M gene knockouts reveal increased cytotoxicity in glioblastoma primary cultures. (doi: 10.1134/S0026893322050156) Mol Biology 56(5): 770-779, 2022

  8. Astakhova EA, Byazrova MG, Yusubalieva GM, Kulemzin SV, Kruglova NA, Prilipov AG, Baklaushev VP, Gorchakov AA, Taranin AV, Filatov AV. Functional profiling of in vitro reactivated memory B cells following natural SARS-CoV-2 infection and Gam-COVID-Vac vaccination. (doi: 10.3390/cells11131991) Cells 11(13): 1991, 2022

  9. Yuzhakova D, Kiseleva E, Shirmanova M, Shcheslavskiy V, Sachkova D, Snopova L, Bederina E, Lukina M, Dudenkova V, Yusubalieva G, Belovezhets T, Matvienko D, Baklaushev V. Highly invasive fluorescent/bioluminescent patient-derived orthotopic model of glioblastoma in mice. (doi: 10.3389/fonc.2022.897839) Front Oncol 12: 897839, 2022

  10. Kulemzin SV, Sergeeva MV, Baranov KO, Gorchakov AA, Guselnikov SV, Belovezhets TN, Volkova OY, Najakshin AM, Chikaev NA, Danilenko DM, Taranin AV. VH3-53/66-Class RBD-specific human monoclonal antibody iB20 displays cross-neutralizing activity against emerging SARS-CoV-2 lineages. (doi: 10.3390/jpm12060895) J Pers Med 12(6): 895, 2022

  11. Byazrova MG, Kulemzin SV, Astakhova EA, Belovezhets TN, Efimov GA, Chikaev AN, Kolotygin IO, Gorchakov AA, Taranin AV, Filatov AV. Memory B cells induced by Sputnik V vaccination produce SARS-CoV-2 neutralizing antibodies upon ex vivo restimulation. (doi: 10.3389/fimmu.2022.840707) Front Immunol 13: 840707, 2022

  12. Merkuleva IA, Shcherbakov DN, Borgoyakova MB, Shanshin DV, Rudometov AP, Karpenko LI, Belenkaya SV, Isaeva AA, Nesmeyanova VS, Kazachinskaia EI, Volosnikova EA, Esina TI, Zaykovskaya AV, Pyankov OV, Borisevich SS, Shelemba AA, Chikaev AN, Ilyichev AA. Comparative immunogenicity of the recombinant receptor-binding domain of protein S SARS-CoV-2 obtained in prokaryotic and mammalian expression systems. (doi: 10.3390/vaccines10010096) Vaccines 10(1): 96, 2022

  13. Smirnov S, Petukhov A, Levchuk K, Kulemzin S, Staliarova A, Lepik K, Shuvalov O, Zaritskey A, Daks A, Fedorova O. Strategies to circumvent the side-effects of immunotherapy using allogeneic CAR-T cells and boost its efficacy: Results of recent clinical trials. (doi: 10.3389/fimmu.2021.780145) Front Immunol 12: 780145, 2021

  14. Kulemzin S, Evsyukov I, Belovezhets T, Taranin A, Gorchakov A. Horses for courses in the era of CARs: Advancing CAR T and CAR NK cell therapies. (doi: 10.3390/jpm11111182) J Pers Med 11(11): 1182, 2021

  15. Gorchakov AA, Kulemzin SV, Guselnikov SV, Baranov KO, Belovezhets TN, Mechetina LV, Volkova OYu, Najakshin AM, Chikaev NA, Chikaev AN, Solodkov PP, Larichev VF, Gulyaeva MA, Markhaev AG, Kononova YuV, Alekseyev AYu, Shestopalov AM, Yusubalieva GM, Klypa TV, Ivanov AV, Valuev-Elliston VT, Baklaushev VP, Taranin AV. Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern. (doi: 10.1038/s41421-021-00340-8) Cell Discov 7: 96, 2021

  16. Smagina AS, Kulemzin SV, Yusubalieva GM, Kedrova AG, Sanzharov AE, Ivanov YV, Matvienko DA, Kalsin VA, Gorchakov AA, Baklaushev VP, Taranin AV. VAV1‐overexpressing YT cells display improved cytotoxicity against malignant cells. (doi: 10.1002/bab.2001) Biotechnol Appl Biochem 68(4): 849-855, 2021

  17. Starostina EV, Sharabrin SV, Antropov DN, Stepanov GA, Shevelev GYu, Lemza AE, Rudometov AP, Borgoyakova MB, Rudometova NB, Marchenko VYu, Danilchenko NV, Chikaev AN, Bazhan SI, Ilyichev AA, Karpenko LI. Construction and immunogenicity of modified mRNA-vaccine variants encoding influenza virus antigens (doi: 10.3390/vaccines9050452) Vaccines 9(5): 452, 2021

​Publication before year 2021 see Laboratory of Immunogenetics

Selected talks: 

  1. Chikaev A. CD47/SIRPa blockers and CARs: together we stand. XII Raisa Gorbacheva Memorial International Symposium "Hematopoietic Stem Cell Transplantation. Gene and Cellular Therapy", 20-22 September 2018, St. Petersburg, Russia

  2. Belovezhets T. Quest for the optimal NK-cell line as a CAR carrier. XII Raisa Gorbacheva Memorial International Symposium "Hematopoietic Stem Cell Transplantation. Gene and Cellular Therapy", 20-22 September 2018, St. Petersburg, Russia

  3. Kulemzin S. Forging the Natural Killer with genome editing. XII Raisa Gorbacheva Memorial International Symposium "Hematopoietic Stem Cell Transplantation. Gene and Cellular Therapy", 20-22 September 2018, St. Petersburg, Russia

  4. Kulemzin SV. Generation of NK-cell lines with enhanced therapeutic potential. International congress “CRISPR-2018”, September 10-14, 2018, Novosibirsk, Russia

  5. Guselnikov S. Evolution of FcR- and KIR-like leukocyte receptors: from Teleostei to Mammalia. Eastern Great Lakes Molecular Evolution Meeting. Koffler Institute for Pharmacy Management, University of Toronto, 30 April 2005, Toronto, Canada

Research Groups

Department of Structure and Function of Chromosomes
Department of Regulation of Genetic Processes